Tafinlar (dabrafenib mesylate) capsules, 50mg (YJ code: 4291046M1020, standard: 50mg 1 capsule), manufactured by Novartis Pharma, are a kinase inhibitor used to treat specific types of melanoma, non-small cell lung cancer (NSCLC), and anaplastic thyroid cancer that have a BRAF V600 gene mutation. It can be used alone or in combination with trametinib to block the action of abnormal BRAF proteins and stop cancer cell growth.
Tafinlar Capsules 50mg
Need more detailed information?
Contact TASAKI PHARMA for product sourcing, availability, or related support (English support available).
